The xF+ assay integrates with the Tempus multimodal database, supporting therapeutic recommendations and clinical research. Originally introduced in 2022, the xF+ panel covers 523 genes spanning ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication ...

CHICAGO, April 29, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication ...